The Senate Appropriations Committee has released its fiscal year 2027 spending bills and the reports that go with them, and the health funding report once again pushes federal agencies to study psychedelics, psilocybin included. The same set of bills, though, keeps the long-running rules that bar federal money from being used to promote legalizing Schedule I drugs, and that stop Washington, D.C. from reducing penalties for them.
Taken together, the documents show where Congress stands on magic mushrooms heading into 2027. Senators want more research and better-prepared clinicians, but they are not moving to loosen the federal ban.
The report attached to the bill funding the Departments of Labor and Health and Human Services has several sections on psychedelics. In one, the committee says it recognizes growing interest in psychedelics' potential therapeutic effects. It encourages the National Institutes of Health to widen its research across its institutes and centers, and to work with the Food and Drug Administration on public-private partnerships that advance therapeutic psychedelic research. The Senate panel has used similar language in earlier years. Its fiscal 2025 report also urged NIH to expand psychedelic research.
A second section focuses on what the committee calls neuroplastogens. It names psilocybin, ibogaine, 5-MeO-DMT, LSD and MDMA, and points to interest in studying them for substance use disorders involving methamphetamine, opioids, cocaine and other stimulants, as well as for co-occurring mental health conditions. The committee encourages the National Institute on Drug Abuse to make this research a priority and to work with the National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, and the FDA.
A third section deals with the workforce. The committee groups psychedelic therapies with other emerging treatments, such as accelerated transcranial magnetic stimulation, and encourages the Substance Abuse and Mental Health Services Administration to assess the training and staffing needed to deliver them. It asks SAMHSA to pay special attention to rural and exurban areas and to regions with many veterans or Medicaid and Medicare patients.
The report also raises concerns about Schedule I itself. The committee writes that restrictions tied to that classification limit how much and what kind of research can be done on certain drugs, psychedelics among them, and says regulatory barriers should be addressed. It credits the National Institute on Drug Abuse with finishing a report on those barriers.
The bill text, however, keeps the status quo. Section 509 of the health funding bill bars using its money for any activity that promotes legalizing a Schedule I drug, except for normal communications between the executive branch and Congress. The separate Financial Services and General Government bill keeps a rider that stops the District of Columbia from using its funds to legalize, or reduce penalties for, recreational possession, use or distribution of any Schedule I substance. That language covers more than cannabis, and psilocybin remains a Schedule I drug under federal law.
Report language guides federal agencies, but it is not binding the way statute is. Its value is in signaling priorities, and the committee's priorities line up with what is happening elsewhere in Washington. Psilocybin drug applications are moving through federal review, and the Department of Veterans Affairs is telling lawmakers it is preparing to deliver psychedelic therapies once they are approved. The workforce section speaks directly to a question Congress keeps asking: who will be trained to provide these treatments, and where.
Academic programs that already run psilocybin research, such as the Yale Program for Psychedelic Science / Connecticut Mental Health Center, The Parsons Research Center for Psychedelic Healing at Mount Sinai and the University of Iowa Psychedelics Research Program, are the kinds of centers that compete for NIH and NIDA support. The nonprofit Usona Institute is one of the groups pushing a psilocybin candidate toward FDA review.
The committee's bills still need floor votes and negotiation with the House before any final fiscal 2027 spending law takes shape. For now, the Senate's message on psilocybin is consistent: study it more, prepare the workforce, and leave the federal ban in place.